Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real MM: VMP +/- Daratumumab vs Rd +/- Daratumumab in ASCT-Ineligible Multiple Myeloma
NCT03829371Phase 4Active, not recruiting
- Sponsor
- University of Turin
- Start
- Jan 2019
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Modified Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bortezomib, melphalan, prednisone, lenalidomide, dexamethasone and 1 more in multiple myeloma (MM) (4 arms), sponsored by University of Turin. Primary endpoint: Progression-free survival at 5 years. Started Jan 2019; status: active, not recruiting.
02
Drugs
bortezomibmelphalanprednisonelenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03829371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829371.